Ticker Hub
MTVA — AI Analysis & Sentiment
3 recent AI-generated analyses for MTVA. Sentiment and confidence insights updated continuously.
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
MetaVia's positive Phase 1 data for DA-1726 and planned study advancement position it for future growth, despite current weak financials. The marke...
Mar 26, 2026MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
MetaVia received IRB approval to advance its obesity drug DA-1726 into higher-dose Phase 1 studies. This progression of a key pipeline asset could ...
Mar 18, 2026MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
MetaVia has secured extended patent protection for Vanoglipel until 2035, a critical step for its clinical-stage drug pipeline. This safeguards the...
Mar 12, 2026